These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 24516999)
1. Screening of commercial cyclic peptides as inhibitor envelope protein dengue virus (DENV) through molecular docking and molecular dynamics. Parikesit AA; Kinanty ; Tambunan US Pak J Biol Sci; 2013 Dec; 16(24):1836-48. PubMed ID: 24516999 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach. Aarthy M; Singh SK Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716 [TBL] [Abstract][Full Text] [Related]
3. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection. Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143 [TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus. Anasir MI; Ramanathan B; Poh CL Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021 [TBL] [Abstract][Full Text] [Related]
5. Conformational and energy evaluations of novel peptides binding to dengue virus envelope protein. Amir-Hassan A; Lee VS; Baharuddin A; Othman S; Xu Y; Huang M; Yusof R; Rahman NA; Othman R J Mol Graph Model; 2017 Jun; 74():273-287. PubMed ID: 28458006 [TBL] [Abstract][Full Text] [Related]
6. Identification of sequence motifs involved in Dengue virus-host interactions. Asnet Mary J; Paramasivan R; Shenbagarathai R J Biomol Struct Dyn; 2016; 34(3):676-87. PubMed ID: 25905427 [TBL] [Abstract][Full Text] [Related]
8. Screening of commercial cyclic peptide conjugated to HIV-1 Tat peptide as inhibitor of N-terminal heptad repeat glycoprotein-2 ectodomain Ebola virus through in silico analysis. Tambunan USF; Alkaff AH; Nasution MAF; Parikesit AA; Kerami D J Mol Graph Model; 2017 Jun; 74():366-378. PubMed ID: 28482272 [TBL] [Abstract][Full Text] [Related]
9. Discovery and design of cyclic peptides as dengue virus inhibitors through structure-based molecular docking. Idrees S; Ashfaq UA Asian Pac J Trop Med; 2014 Jul; 7(7):513-6. PubMed ID: 25063278 [TBL] [Abstract][Full Text] [Related]
10. Epitopes based drug design for dengue virus envelope protein: A computational approach. Wadood A; Mehmood A; Khan H; Ilyas M; Ahmad A; Alarjah M; Abu-Izneid T Comput Biol Chem; 2017 Dec; 71():152-160. PubMed ID: 29096381 [TBL] [Abstract][Full Text] [Related]
11. Targeting domain-III hinging of dengue envelope (DENV-2) protein by MD simulations, docking and free energy calculations. Dubey KD; Tiwari G; Ojha RP J Mol Model; 2017 Apr; 23(4):102. PubMed ID: 28255859 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity. Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222 [TBL] [Abstract][Full Text] [Related]
13. Dynamics and binding interactions of peptide inhibitors of dengue virus entry. Isa DM; Chin SP; Chong WL; Zain SM; Rahman NA; Lee VS J Biol Phys; 2019 Mar; 45(1):63-76. PubMed ID: 30680580 [TBL] [Abstract][Full Text] [Related]
14. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections. Ajmal A; Shahab M; Waqas M; Zheng G; Zulfat M; Bin Jardan YA; Wondmie GF; Bourhia M; Ali I Sci Rep; 2024 Jun; 14(1):13130. PubMed ID: 38849372 [TBL] [Abstract][Full Text] [Related]
15. Receptor-Guided De Novo Design of Dengue Envelope Protein Inhibitors. Desai VH; Kumar SP; Pandya HA; Solanki HA Appl Biochem Biotechnol; 2015 Oct; 177(4):861-78. PubMed ID: 26299376 [TBL] [Abstract][Full Text] [Related]
16. Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication. Abdul Ahmad SA; Palanisamy UD; Tejo BA; Chew MF; Tham HW; Syed Hassan S Virol J; 2017 Nov; 14(1):229. PubMed ID: 29162124 [TBL] [Abstract][Full Text] [Related]
17. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies. Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382 [TBL] [Abstract][Full Text] [Related]
19. Anti-dengue virus activity of scytovirin and evaluation of point mutation effects by molecular dynamics and binding free energy calculations. Siqueira AS; Jerônimo Lima AR; de Souza RC; Santos AS; da Silva Gonçalves Vianez Júnior JL; Gonçalves EC Biochem Biophys Res Commun; 2017 Aug; 490(3):1033-1038. PubMed ID: 28666874 [TBL] [Abstract][Full Text] [Related]
20. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation. Ahmed M; Kumar A; Hobman TC; Barakat K J Mol Graph Model; 2019 Jul; 90():128-143. PubMed ID: 31082639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]